• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Latest Data on Transplacental Antibody Transfer Following COVID-19 Vaccination

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Prabhu et al. (Obstetrics & Gynecology, 2021) examined the immunologic response to COVID-19 mRNA vaccination in pregnancy, including transplacental transfer of maternal antibodies

METHODS:

  • Cohort study
  • Participants
    • Pregnant women with cord blood availability following delivery
    • Received one or both doses of an mRNA–based COVID-19 vaccine
    •  Singleton neonate
    • Exclusions: Positive test against nucleocapsid protein (to verify that antibodies derived from vaccination rather than previous SARS-CoV-2 infection)
  • Study design
    • Semi-quantitative testing for antibodies was performed on clinical sera
      • Maternal peripheral blood
      • Cord blood
    • Relationship between maternal and cord blood IgG antibody levels and IgG placental transfer (neonatal/maternal) were assessed  

RESULTS:

  • 122 pregnant women
    • One vaccine dose: 55 women
    • Two doses: 67 women
  • Antibody response at birth
    • IgG antibodies detected: 87 women
    • IgG and IgM antibodies detected: 19 women
    • No antibody response: 16 women, all of whom were <4 weeks after their first vaccine dose
  • All women and cord blood samples, except for one, had detectable IgG antibodies ≥4 weeks after the first vaccine
    • Detectable IgG in cord blood at delivery, after first dose: 44%
    • Detectable IgG in cord blood at delivery, after second dose: 99%
  • The earliest detection of antibodies
    • In maternal blood: 5 days post first vaccine dose
    • In cord blood: 16 days post first vaccine dose
  • Maternal IgG levels were significantly higher, week by week, ≥2 weeks after the first vaccine dose (P = 0.005)

CONCLUSION:

  • Women who received an mRNA COVID-19 vaccine during pregnancy mounted an antibody response as early as 5 days after their first dose
  • Antibodies were present in cord blood as early as 16 days after the first dose
  • The authors state

The increasing levels of maternal IgG over time and the increasing placental IgG transfer ratio over time suggest that timing between vaccination and birth may be an important factor to consider in vaccination strategies of pregnant women

Given the variability in antibody transfer and lack of transfer to one neonate, further studies are needed to understand the factors that influence transplacental transfer of IgG antibodies, as well as the protective nature of these antibodies

Learn More – Primary Sources:

Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Guidance on COVID-19 Vaccine Including Pregnancy
mRNA COVID-19 Vaccine Safety in Pregnant Women
Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?
How Efficient is Transplacental Transfer of SARS-CoV-2 Antibodies?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site